Androgen deprivation therapy for prostate cancer and osteoporotic risk;Suppression androgénique dans le cancer de la prostate et risque ostéoporotique

Progres en Urologie

Volumn 22, Issue SUPPL. 2, 2012, Pages

  Cortet, B ^a   Lartigau, E ^b   Caty, A ^b   Moulinier, F ^c   Staerman, F ^d   Villamizar Vesga, J ^e   Villers, A ^f  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c Service d'Urologie   (France)

^d Polyclinique Les Bleuets   (France)

^e Service d'Urologie   (France)

^f UNIV LILLE   (France)

Author keywords

Androgenic deprivation; Antagonists; Castration; Fractures; Osteoporosis; Prostate; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN;

ARTICLE; CHEMICALLY INDUCED DISORDER; FRAGILITY FRACTURE; HUMAN; MALE; OSTEOPOROSIS; PROSTATE TUMOR; QUESTIONNAIRE; RISK ASSESSMENT;

ANDROGEN ANTAGONISTS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT;

EID: 84867962255     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(12)70034-9     Document Type: Article

References (27)

1. Briot K., Cortet B., Trémollières F., Sutter B., Thomas T., Roux C., et al. Male osteoporosis: diagnosis and fracture risk evaluation. Joint Bone Spine 2009, 76:129-133.
2. Villers A., Grosclaude P. épidémiologie du cancer de la prostate. Méd Nuc 2008, 32:2-4.
3. Drouin S.J., Rouprêt M. Actualités dans les cancers de prostate non localisés: diagnostic, traitement et voies d'avenir. Prog Urol 2010, 20(Suppl 3):S198-S202.
4. Salomon L., Azria D., Bastide C., Beuzeboc P., Cormier L., Cornud F., et al. Oncology Committee of the French Association of Urology (CCAFU). Recommendations Onco- Urology 2010: Prostate cancer. Prog Urol 2010, 20(Suppl 4):S217-S251.
5. Eriksson S., Eriksson A., Stege R., Carlström K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995, 57:97-99.
6. Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., Tavernier C. Bone mineral density in men treated with synthetic gonadotropin- releasing hormone agonists for prostatic carcinoma. J Urol 1999, 161:1219-1222.
7. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163:181-186.
8. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
9. Mittan D., Lee S., Miller E., Perez R.C., Basler J.W., Bruder J.M. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656-3661.
10. Smith M.R., Fallon M.A., Goode M.J. Cross- sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003, 61:127-131.
11. Alibhai S., Yun L., Cheung A., Paszat L. Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 2012, 307:255-256.
12. Townsend M.F., Sanders W.H., Northway R.O., Graham S.D. Bone fractures associated with luteinizing hormone- releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997, 79:545-550.
13. Oefelein M.G., Ricchuiti V., Conrad W., Seftel A., Bodner D., Goldman H., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001, 166:1724-1728.
14. Oefelein M.G., Ricchiuti V., Conrad W., Resnick M.I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005-1007.
15. Alibhai S.M., Duong-Hua M., Cheung A.M., Sutradhar R., Warde P., Fleshner N.E., et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010, 184:918-923.
16. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046.
17. Neuprez A., Johansson H., Kanis J.A., Mccloskey E.V., Odén A., Bruyère O., et al. Rationalisation du remboursement des médicaments de l'ostéoporose: de la mesure isolée de la densité osseuse à l'intégration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX®. Rev Med Liège 2009, 64:612-619.
18. http://www.shef.ac.uk.FRAX.
19. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
20. Saylor P.J., Kaufman D.S., Michaelson M.D., Lee R.J., Smith M.R. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010, 183:2200-2205.
21. de la Rosette J., Davis R., Frankel D., Olesen K. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. Int J Clin Pract 2011, 65:559-566.
22. Sun L., Peng Y., Sharrow A.C., Iqbal J., Zhang Z., Papachristou D.J., et al. FSH directly regulates bone mass. Cell 2006, 125:247-260.
23. Muir V.J., Scott L.J. Denosumab: in cancer treatment- induced bone loss. BioDrugs 2010, 24:379-386.
24. Benhamou C.L., Souberbielle J.C., Cortet B., Fardellone P., Gauvain J.-B., Thomas T., et al. La vitamine D chez l'adulte: recommandations du GRIO. Presse Med 2011, 40:673-682.
25. Haute Autorité de Santé. Prévention, Diagnostic et traitement de l'ostéoporose. Note de synthèse, juillet 2006.
26. Egerdie B., Saad F. Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options. Can Urol Assoc J 2010, 4:129-135.
27. Michaud L.B. Managing cancer treatment- induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 2010, 67:S20-S30.